Stem Cell Manufacturing Market Growth Rate, CAGR, Key Players Analysis Report 2028

The global Stem Cell Manufacturing Market in terms of revenue was estimated to be worth $12.7 billion in 2023 and is poised to reach $21.8 billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The key factors driving the growth of the global stem cell manufacturing market are rising awareness about stem cell products in clinical applications and technical advancements in stem cell manufacturing. However, stringent regulatory policies are expected to restrain market growth to a certain extent.

Download a FREE Sample Copy of the Global Stem Cell Manufacturing Market Research Report at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=70743403&utm_source=Ganesh&utm_medium=P

Stem Cell Manufacturing Market Ecosystem
Prominent companies in the market include well-established, financially stable manufacturers of stem cell manufacturing products. These companies have been operating in the market for several years and possess diversified, state-of-the-art technologies, product portfolios, and strong global sales and marketing networks. Prominent companies in this market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza Group (Switzerland), Danaher Corporation (US), Sartorius AG (Germany), Becton, Dickinson, and Company (US), Eppendorf AG (Germany), Corning Inc. (US), Bio-Rad Laboratories (US), Takara Bio Group (Japan), Fujifilm Holdings Corporation (Japan), Getinge AB (Sweden), Terumo Corporation (Japan), Bio-Techne Corporation (US), HiMedia Laboratories (India), StemCell Technologies, Inc. (Canada), Miltenyi Biotec GmBH (Germany), PromoCell (Germany), Anterogen Co. Ltd. (South Korea), CellGenix GmBH (India), Pluristem Therapeutics Inc. (Israel), Daiichi Sankyo (Japan), Organogenesis Holdings Inc. (US), Vericel Corporation (US), and American Cryostem Corporation (US).

The consumables segment accounted for the largest share of the product segment in the stem cell manufacturing industry in 2023.
Based on products, the stem cell manufacturing market is categorized into consumables, instruments, and stem cell lines. In 2023, the consumables segment accounted for the largest share of the stem cell manufacturing market. The major driver propelling the increasing demand for regenerative therapies, advancements in stem cell research, and increasing potential in treating various diseases, driving the need for efficient and reliable manufacturing processes.

This report categorizes the stem cell manufacturing market to forecast revenue and analyze trends in each of the following submarkets:
By Product
• Consumables
o Culture Media
o Other Consumables

• Instruments
o Bioreactors and Incubators
o Cell Sorters
o Other Instruments

• Stem Cell Lines
o Hematopoietic stem cells (HSC)
o Mesenchymal stem cells (MSC)
o Induced Pluripotent Stem cells (iPSC)
o Embryonic stem cells (ESC)
o Neural Stem cells (NSC)
o Multipotent adult progenitor stem cells

By Application
• Research Applications
o Life science research
o Drug discovery and development

• Clinical Application
o Allogenic stem cell therapy
o Autologous stem cell therapy

• Cell & Tissue Banking Applications

By End User
• Pharmaceutical & Biotechnology Companies
• Academic institutes, Research laboratories & contract research organizations
• Hospitals & surgical centers
• Cell & tissue banks
• Other End Users

By Region
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o Japan
o India
o China
o Rest of Asia Pacific (RoAPAC)
• Latin America
• Middle East Africa

Direct Purchase of the Global Stem Cell Manufacturing Market Research Report at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=70743403&utm_source=Ganesh&utm_medium=P

The pharmaceutical & biotechnology companies segment dominated the end-user segment in the stem cell manufacturing industry in 2023.
Based on the end user, the segment of the stem cell manufacturing market is categorized into hospitals & surgical centers; pharmaceutical & biotechnology companies; cell & tissue banks; academic institutes, research laboratories, and CROs; and other end users. In 2023, the pharmaceutical & biotechnology companies segment dominated the end-user segment with the highest revenue share. The growing demand for regenerative medicine and increasing strategic collaborations to accelerate the development and commercialization of stem cell-based therapies.

North America was the largest market for stem cell manufacturing industry in 2023
Geographically, the stem cell manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. The stem cell manufacturing market is dominated by North America in 2023, and this dominance is anticipated to continue throughout the forecast period. The established research infrastructure, technological advancements, demand for precision medicine, supportive regulatory environment, robust biotechnology and healthcare industry, and availability of funding and investment drive the growth of the stem cell manufacturing market in North America. However, the high cost associated with research and products, which can limit the adoption of these products for some end users, especially smaller research institutions with limited budgets, are negatively impacting the market growth.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road Suite 430 Northbrook, IL 60062
USA : 1-888-600-6441 sales@marketsandmarkets.com

MarketsandMarkets was founded in 2009 with a simple, yet powerful, idea - every disruption is inherently the source of game-changing business opportunities. At that time, everybody was talking about disruptive trends such as AI, IoT, 3D printing, nanotech, robotics, etc. but nobody was certain about the business opportunities associated with them. Upon sensing this significant white space, MarketsandMarkets started exploring these emerging and fast-growing opportunities and soon realized that it was part of a much bigger game. We figured out that the B2B economy was just beginning to undergo a dramatic transformation, wherein roughly $25 trillion of new revenue sources would emerge by the end of 2030. So, we embarked on a journey to help B2B companies monetize their play in this phenomenon.

This release was published on openPR.